PFEPfizerFinished
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Non-small Cell Lung Cancer · Pancreatic Cancer · Colorectal Cancer · Loss of Appetite · Fatigue · Cachexia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 187 (final count)
- Started
- Nov 21, 2022
- Main results expected
- Mar 13, 2024
- Fully finished
- Apr 23, 2025
- Results posted
- Apr 29, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: Change From Baseline in Body Weight at Week 12
Measured over: Baseline, Week 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05546476 · record last updated 2026-06-03 · checked 2026-11-09 15:42 UTC